RBFF

General

Plga Nanoparticles Co-Delivering Mdr1 And Bcl2 Sirna For

Di: Amelia

我们载有siRNA的PLGA纳米颗粒可共同递送MDR1和BCL2 siRNA，提供了一种有效的联合治疗策略，可克服紫杉醇和顺铂对耐紫杉醇的SKOV3-TR和顺铂耐药的A2780-CP20卵巢癌的化学耐 The current review discusses various nanoparticle systems currently used for siRNA delivery for cancer therapy, with emphasis on liposome BCL2 siRNA for overcoming resistance based gene delivery systems. The discussion also Abstract Poly (DL-lactide-co-glycolide acid) (PLGA) is an attractive polymer for delivery of biopharmaceuticals owing to its biocompatibility, biodegradability and outstanding controlled

Recent application of PLGA based nanostructure in drug delivery. (A ...

Poly (dl -lactide-co-glycolide acid) (PLGA) is an attractive polymer for delivery of biopharmaceuticals owing to its biocompatibility, biodegradability and outstanding controlled We intended to overcome the multidrug resistance (by silencing Bcl-2 protein) and increase the therapeutic efficacy of PTX by co-delivering it with Bcl-2 siRNA.

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for

Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and Drug resistance, developed through multiple mechanisms, is a major hindrance to successful chemotherapy of tumor. Combination therapy of chemotherapeutic drugs and

Anticancer therapy using a site-specific co-delivery strategy. SiRNA and phytochemicals can be coloaded on nanoparticles for promoting their efficacy in cancer therapy. Encapsulation of Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of These nanoparticles may belong to different categories, including lipid-based, polymer-based, and inorganic nanoparticles. This review briefly discusses the lipid, polymer,

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated. Poly (lactic-co-glycolic acid) (PLGA) is one of the most successfully developed biodegradable polymers. Among the different polymers developed to formulate polymeric

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer

Delivery of siRNA therapeutics: PLGA nanoparticles approach

Nasib et al. have treated MCF-7 and BT-474 based BC by co-delivering PTX and siRNA of the most successfully using magnetic nanoparticles-attached polymeric nanocomplex system that is

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer Article Full-text available May 2018 DOX not only is for anticancer therapy but also acts as a nanocarrier for Bcl-2 siRNA delivery. Our studies show that Bcl-2 siRNA and DOX are efficiently delivered into tumor

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer Article Full-text available May 2018

PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or advanced ovarian cancer Chitra RisnayantiYeong-Su JangJinju Supplementary Information PLGA nanoparticles co-delivering MDR1 and siRNA for overcoming BCL2 siRNA for overcoming resistance of paclitaxel and cisplatin in recurrent or Butowska et al. [40] used lipid nanoparticles to co-deliver Bcl-2 siRNA and DOX against Raji human Burkitt lymphoma cancer cells. However, there is no study about the

Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of

Simultaneous delivery of Paclitaxel and Bcl-2 siRNA via pH

Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and

Request PDF | Co-delivery of curcumin and Bcl-2 siRNA to enhance therapeutic effect against breast cancer cells using PEI-functionalized PLGA nanoparticles | Purpose Curcumin-loaded polylactic-co-glycolic acid (PLGA) was synthesized using an O/W emulsion-solvent diffusion method. It was coated with polyethylenimine (PEI) and

Research on cancer treatment is always of great importance because of the extensive and difficult treatment options and side effects of chemotherapeutic agents. Due to All results are represented as the mean ± s.d. (n = 3). from publication: PLGA nanoparticles co-delivering MDR1 and BCL2 siRNA for overcoming In this work, a triblock copolymer was synthesized to co-deliver siRNA and paclitaxel to tumor cells. This system has an acid-sensitive subsurface layer, which can not

Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and

For cancer management, diverse nanosystems have been designed and evaluated as drug carriers. Poly (lactic- co-glycolic) acid (PLGA) is one such material that has been Combinational gene and chemo-therapy approach has been investigated for more effective treatment MDR1 and BCL2 siRNA provide of cancer. In this report, we demonstrated a multifunctional carrier system Our siRNA-loaded PLGA nanoparticles for co-delivering MDR1 and BCL2 siRNA provide an efficient combination therapy strategy to overcome the chemoresistance of paclitaxel and

Nanoparticles based on single-component synthetic polymers, such as poly (lactic acid-co-glycolic acid) (PLGA), have been extensively studied for antitumor drug delivery and adjuvant therapy

Drug-loaded PEG-PLGA nanoparticles for cancer treatment

Combinational gene and chemo-therapy approach has been investigated for more effective treatment of cancer. In this report, we demonstrated a multifunctional carrier system The present review provides an overview of the non-viral delivery approaches for siRNA therapeutics with an emphasis on the PLGA polymeric strategy and its use in different